Cross-protective Efficacy of NA-based mRNA Influenza Vaccine Candidates

707 post-2009 A(H1N1)pdm09 NA sequences were analyzed computationally to design mRNA vaccine constructs. The dataset likely contains results from mouse immunization and challenge studies, including antibody titers and protection metrics. The work was authored by Hyunbeen Kim and published on figshare in April 2026.

Use Cases

• Evaluate homologous vaccine protection efficacy based on NA-specific antibody titers.
• Assess heterologous vaccine protection efficacy against different influenza strains.
• Model antigenic similarity between vaccine constructs and viral NA sequences.
• Design dual-antigen (HA + NA) vaccine strategies using computational guidance.

Strengths

• Analysis includes 707 influenza NA sequences, providing a substantial basis for computational design.
• Experimental results from mouse challenge studies are likely included.
• Dataset is openly licensed under CC-BY-4.0.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is stored in a PDF format (3.0 MB), which may require extraction for structured analysis.

Provenance

Source

figshare

Collection Method

Computational analysis of viral sequences followed by experimental validation.

Time Range

Sequences are post-2009 A(H1N1)pdm09.

Freshness

Last updated 2026-04-09 05:14:54; freshness should be verified.